Drugs / TAK-243
TAK-243
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06223542 | Mar 2025 → Apr 2027 expected | adult lymphoma, metastatic malignant neoplasm, non-Hodgkin lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT03816319 | Mar 2025 → Oct 2026 | acute myeloid leukemia, myelodysplastic syndrome with excess blasts | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 1 | NCT02045095 | Jan 2014 → Nov 2016 | cancer | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-243 | “TAK-243” NCT03816319 ↗ |
| Known as | AOB 87172 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297405 ↗ |
| Known as | MLN7243 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02045095 ↗ |
| Known as | TAK-243 (MLN7243) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297405 ↗ |
| Known as | UAE INHIBITOR MLN7243 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297405 ↗ |
| Action | Inhibit | “MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE)” NCT02045095 ↗ |
| Modality | Small molecule | — CHEMBL4297405 ↗ |
| Route | Intravenous | “Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.” NCT02045095 ↗ |